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Abstract
Background: India, China and Russia account for more than 62% of multidrug resistant
tuberculosis (MDRTB) globally. Within India, locations like urban metropolitan Mumbai with its
burgeoning population and high incidence of TB are suspected to be a focus for MDRTB. However
apart from sporadic surveys at watched sites in the country, there has been no systematic attempt
by the Revised National Tuberculosis Control Programme (RNTCP) of India to determine the
extent of MDRTB in Mumbai that could feed into national estimates. Drug susceptibility testing
(DST) is not routinely performed as a part of programme policy and public health laboratory
infrastructure, is limited and poorly equipped to cope with large scale testing.
Methods: From April 2004 to January 2007 we determined the extent of drug resistance in 724
{493 newly diagnosed, previously untreated and 231 first line treatment failures (sputum-smear
positive at the fifth month after commencement of therapy)} cases of pulmonary tuberculosis
drawn from the RNTCP in four suboptimally performing municipal wards of Mumbai. The
observations were obtained using a modified radiorespirometric Buddemeyer assay and validated
by the Swedish Institute for Infectious Disease Control, Stockholm, a supranational reference
laboratory. Data was analyzed utilizing SPSS 10.0 and Epi Info 2002.
Results: This study undertaken for the first time in RNTCP outpatients in Mumbai reveals a high
proportion of MDRTB strains in both previously untreated (24%) and treatment-failure cases
(41%). Amongst new cases, resistance to 3 or 4 drug combinations (amplified drug resistance)
including isoniazid (H) and rifampicin (R), was greater (20%) than resistance to H and R alone (4%)
at any point in time during the study. The trend for monoresistance was similar in both groups
remaining highest to H and lowest to R. External quality control revealed good agreement for H
and R resistance (k = 0.77 and 0.76 respectively).
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BMC Public Health 2009, 9:211 http://www.biomedcentral.com/1471-2458/9/211Conclusion: Levels of MDRTB are much higher in both previously untreated and first line
treatment-failure cases in the selected wards in Mumbai than those projected by national estimates.
The finding of amplified drug resistance suggests the presence of a well entrenched MDRTB
scenario. This study suggests that a wider set of surveillance sites are needed to obtain a more
realistic view of the true MDRTB rates throughout the country. This would assist in the planning
of an adequate response to the diagnosis and care of MDRTB.
Background
India, designated as a 'high burden' country for tuberculo-
sis (TB) has also been identified as a hot spot region for
multi-drug-resistant Mycobacterium tuberculosis (MDRTB)
infection [1,2]. Together India, China and Russia account
for more than 62% of the global MDRTB burden [3]. Yet
in the WHO Reports on global TB control, MDRTB in
India continues to be reported between 2.5–2.8% and
14–17% amongst new TB and retreated patients respec-
tively [4-8].
These reports are limited because of relatively small sam-
ple size, the absence of explicit criteria for patient selec-
tion, unclear definitions of retreatment, absence of quality
control in laboratory methods and geographic restriction
to sentinel sites (in which programme performance may
exceed that of routinely monitored locations). Addition-
ally the cases sampled from surveys in fixed sentinel sites
in India approximate only 7% of the estimated MDRTB
load of 110,132, in contrast to South Africa which has
sampled almost 38% of its estimated burden of 14,034
MDRTB cases uniformly from different regions of the
country [9,7]. The multiple challenges in measurement of
the true burden of MDRTB are presented by Cohen et al
2007 [10]. They suggest that periodic surveys (the prime
method for assessing levels of MDRTB in resource defi-
cient settings) may underestimate total MDRTB burden
because acquired drug resistant cases are undercounted
and resistance amongst prevalent cases is not assessed.
Currently a 5 year (2006–2010) surveillance for drug
resistance is being carried out in 10 states in India [11]. A
preliminary report providing limited information from
surveillance in 2 states concludes that the prevalence of
MDRTB is ~3% in new cases and 12–18% amongst re-
treatment cases. It furthermore concludes that there has
been no increase in drug resistance over the past years as
shown by studies from Tuberculosis Research Center,
Chennai [11].
In contrast to these national and WHO reports, key stud-
ies from a private tertiary care facility in the TB hyperen-
demic metropolitan city of Mumbai in Western India in
2006 reported increasing trends of MDRTB in new and
retreated cases [12]. Their report published in 2003
quotes MDRTB in new cases at 30% and in treated cases at
60% [13]. A recent report from the same centre high-
lighted the presence of 8% XDRTB in a subset of their
MDRTB cases [14]. These figures generated through pur-
posive sampling of patients accessing a tertiary care centre
are critiqued by the national control programme as
"unrepresentative". However despite being open to refer-
ral bias, they are clearly a cause for concern.
There are no community based data on MDRTB from an
endemic setting such as Mumbai because drug susceptibil-
ity testing (DST) is not routinely carried out as a part of
programme policy and the public health laboratory infra-
structure is limited and ill equipped to cope with large
scale testing. Only two intermediate reference laboratories
have been established and accredited in the States of
Maharashtra and Gujarat, whilst 11 other such State labo-
ratories are still in the process of accreditation [15].
Our aim therefore, was to gain a community based esti-
mate of the levels of drug resistance in previously
untreated new and first line treatment-failure cases. This
was undertaken in selected wards of Mumbai, a city vul-
nerable to drug-resistant disease because of its high popu-
lation density, high prevalence of TB (299/100,000) [7]
and an overstretched public, coupled with an unregulated
private, health sectors [16]. Since conditions in Mumbai
are likely to be markedly different from sentinel sites, it
was considered likely that rates of MDRTB in Mumbai
may differ substantially from published national esti-
mates.
Methods
Location of study
The Revised National Tuberculosis Control Programme
(RNTCP) in Mumbai is implemented in individual wards
of the city. Since this study was part of a larger epidemio-
logical project on transmission of MDRTB in an endemic
setting, 4 centrally located wards F/N, G/N, H/E, and K/E
characterized by a high sputum-positive case load, with
moderately suboptimal cure rates ranging between 78–
81% were selected. Fifty percent of the wards in Mumbai
(11/23) displayed similar cure rates; an additional 20% of
the wards even further reduced cure rates of 50–74%
(RNTCP quarterly reports 2001). These 4 moderately sub-
optimal performing wards were selected to minimize the
possibility of extreme outcomes due to selection bias. As
far as could be ascertained there was no apparent devia-
tion in the RNTCP functioning in these wards comparedPage 2 of 9
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the resident population of these 4 selected wards
belonged either to the middle/lower socioeconomic class
and resided in informal housing in slums and were there-
fore thought to be representative. Cumulatively the 4
wards comprised of 38 DOTS Centers, covering a popula-
tion of 3 million. Each field worker covered an average of
9 DOTS Centers on a thrice weekly basis.
Calculation of sample size
Sample size was based on an earlier study which reported
30% and 60% MDRTB in new and retreated cases respec-
tively from the same setting albeit from a tertiary care cen-
tre treating outpatients [13]. Thus based on an absolute
error of 8% at 95% confidence, the sample size for previ-
ously untreated cases and first line treatment-failures [viz.
sputum-smear positive at the fifth month after com-
mencement of a 2(HERZ)3 + 4(HR)3 regimen comprising
of 2 months of HERZ thrice weekly followed by 4 months
of HR thrice weekly] was estimated to be 224 and 47
respectively.
Patient classification and recruitment
Since the patient sample was drawn from suboptimally
performing wards, the procedure for screening and
recruitment of patients was designed to project balanced
figures for MDRTB levels and minimize bias caused by
previous TB treatment and interruption in treatment of
more than 2 weeks.
During the study period from April 2004 to January 2007,
two groups of sputum smear-positive pulmonary TB
patients registered with the RNTCP DOTS (Directly
Observed Therapy Short Course) Centers were identified
for inclusion. These consisted of – i) newly diagnosed,
previously untreated patients at onset of therapy and ii)
first line treatment-failures {viz. sputum positive at the
fifth month after commencement of a 2(HERZ)3 + 4(HR)3
regimen} (Figure 1). Field workers scrutinized treatment
cards and District TB registers. In keeping with the larger
study objective of investigating MDRTB transmission, the
selection of as many new cases as was logistically feasible
at a DOTS center was attempted subsequent to the con-
firmed presence of a first line treatment-failure at the same
Center. Furthermore screening was based solely on
patient availability and contact at the health posts. Logis-
tical feasibility was influenced by factors such as the low
ratio of field workers to health posts, extreme climatic
conditions compounding difficult transport logistics and
delays in systemic documentation of new patients in reg-
isters.
Inclusion criteria for patients included i) smear-positivity,
ii) age 15–70 years (to exclude those patients with a non-
productive cough), iii) residency in Mumbai for at least 3
years immediately prior to diagnosis and (iv) residency in
the same area as the health posts where treatment was
sought. Patients with a definitive past history of TB or
antitubercular therapy prior to the existing episode, as
determined through a schedule and/or scrutiny of district
TB registers and patients who interrupted treatment for
more than 2 weeks (in case of first line treatment-failures)
were excluded to minimize bias towards MDRTB detec-
tion [17]. As far as could be ascertained, patients in the
Study designFigure 1
Study design.
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lar therapy prior to the current episode.
Besides preliminary scrutiny of treatment cards and Dis-
trict TB registers to identify the 2 groups of patients
(untreated and treatment-failures), screening was directed
through a standard schedule to i) detect past history of TB/
antitubercular treatment, ii) determine period of resi-
dency in Mumbai and iii) detect occurrence of treatment
interruption in treatment-failures. Patients were recruited
after informed consent and referred to Voluntary Coun-
seling and Testing Centers for HIV counseling and testing.
Clearance for this study was obtained from the Founda-
tion for Medical Research (FMR) Institutional Ethics
Committee (20.07.2001/01).
Drug susceptibility testing
Early morning sputum samples from patients were proc-
essed by the modified Petroff's method [18], stained by
Ziehl-Neelsen Carbol Fuchsin, microscopically examined
and cultured on Lowenstein-Jensen slopes (Himedia,
India) as well as in Dubos broth (Himedia, India). Cul-
ture-negative or contaminated samples (~3%) were
excluded from the analysis. Biochemical tests for niacin
and catalase production were performed to confirm the
identity of Mycobacterium tuberculosis. Drug susceptibility
testing of the samples was performed by the radiorespiro-
metric Buddemeyer technique (a manual modification of
the Bactec 460 technique) [19,20]. Briefly, samples were
inoculated into Dubos broth containing 14C Palmitic acid
(Board of Radiation and Isotope Technology, India). Vials
were set up in triplicate each containing 0.5 × 106/ml of
Acid Fast Bacilli (AFBs) in absence (positive control) as
well as presence of drugs (μgs/ml): Isoniazid (H – 0.1),
Rifampicin (R – 2), Pyrazinamide (Z – 100) and Etham-
butol (E – 2.5). Negative controls consisted of medium
without acid fast bacilli (AFBs) as well as with heat killed
AFBs. A 1:100 dilution of the positive control was also
maintained. Readings were obtained daily until the eighth
day in counts per minute (cpm) on a Wallac 1409 DSA
liquid scintillation counter. Growth indices (GI) were cal-
culated for the drug containing vials and the 1:100 posi-
tive control. Difference in growth indices (ΔGI), identical
to that applied in the Bactec 460 method, calculated over
consecutive days was used to determine susceptibility. The
value of the mean ΔGI in the triplicate drug containing
vials was compared to that for 1:100 control for the same
day. If ΔGI was less in the drug containing vials than the
1:100 control, the bacteria were considered susceptible; if
more, they were considered resistant [21,22].
Multidrug resistance (MDR) was defined as resistance to
at least H and R. Other cases were categorized as follows:
Drug sensitive – absence of resistance to any of the drugs,
monoresistance – resistance to only 1 drug and polyre-
sistance – resistance to at least two or more drugs exclud-
ing the HR combination.
Quality Control
External and Internal Validity
Ten percent of the clinical mycobacterial isolates were sent
single-blinded to the Swedish Institute for Infectious Dis-
ease Control, Stockholm, a WHO/IUATLD supranational
reference laboratory for external quality assurance of the
DST of the Mycobacterium tuberculosis isolates by the Bactec
460 method. Isolates were also retested in our laboratory
to determine reproducibility of the results. The isolates
were subcultured in Dubos medium for 4 weeks before
retesting. For discordant drug susceptibility results
between the two laboratories, the results of the suprana-
tional referral laboratory have been reported whilst for
internally discordant results, the initial results have been
presented.
Statistical analysis
The data was analyzed utilizing SPSS version 10.0 and Epi
Info 2002 using Chi square tests. An age group stratifica-
tion of 15–35 yrs, 36–55 yrs and 56–69 yrs was applied
for purposes of analysis. The agreement of DST between
our laboratory and the Swedish Institute for Infectious
Disease Control, Stockholm, was ascertained through
generation of kappa values individually for the four first
line drugs [23]. The kappa values were interpreted as fol-
lows: ≤ 0.40 = Poor, 0.4 – 0.75 = Good, > 0.75 = Excellent.
Comparisons were further expressed in terms of 'sensitiv-
ity' and 'specificity' for the four drugs using standard defi-
nitions.
Results
Patient selection
A total of 1,454 patients (1,136 previously untreated and
318 first line treatment-failures) were screened at the
health posts between April 2004 and January 2007. Of the
2,184 smear positive cases presenting to the RNTCP for
diagnosis, 1,136 (52%) were screened due to reasons out-
lined previously.
Finally, based on the inclusion criteria described earlier,
724 cases comprising of 493 previously untreated and 231
first line treatment-failure cases were recruited. A similar
number namely 730 cases (643 previously untreated and
87 first line treatment-failures) had to be excluded. The
various reasons for exclusion were prior antitubercular
treatment for more than 1 month, residency outside
Mumbai, accessing the private sector in preference to the
RNTCP and transfer to a different DOTS center or inter-
ruption in treatment for more than 2 weeks (only in case
of treatment-failures) (Figure 1).Page 4 of 9
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Of the 724 recruited cases, the majority belonged to the
15–35 yrs age group; 73% (359/493) among previously
untreated cases and 66% (153/231) among first line treat-
ment-failures. The majority were male with no difference
in gender distribution between the previously untreated
cases – 301/493 (61%) and first line treatment-failures –
139/231 (60%). The HIV positivity rate was also compa-
rable at 5% and 3% respectively in the 2 groups (p =
0.105).
Drug susceptibility testing
Newly diagnosed, previously untreated
A high level of drug resistance was seen amongst the pre-
viously untreated cases. Amongst the MDR patients
(24%), the proportion of resistance to 3 or more drugs
including HR (20%) was greater than that of resistance to
HR only (4%) (Table 1). Monoresistance was highest to H
at 11% (53/493) and lowest to R at 1% (3/493) with 5%
resistant to Z (27/493). No association between drug sus-
ceptibility and age could be determined by univariate
analysis.
Strikingly, at all 11 three monthly intervals of the study,
the cumulative proportion of previously untreated cases
resistant to 3 or more drugs inclusive of HR was higher
than that resistant to HR alone (Figure 2).
First line treatment-failures
As expected, a high proportion of MDRTB and polyresist-
ance, 41% (95/231) and 26% (59/231) respectively, was
observed amongst the first line treatment-failures. A sig-
nificantly higher proportion of failures who were MDR
were in the age group of 36–55 years as compared to those
whose strains were sensitive/monoresistant (p < 0.022). A
significantly higher number of treatment-failures were
MDR as compared to the new cases (p = 0.0). The monore-
sistance profile for the 4 drugs tested was similar to that
seen in previously untreated cases remaining highest to H
at 7% (17/231) and lowest to R at 2% (4/231), 4% show-
ing resistance to Z (10/231). No association was detected
between the drug susceptibility profiles of the strains and
the HIV status of the patients within either group.
Quality Control
Kappa scores showed excellent agreement (range 0.76–
0.77), between the drug sensitivity results obtained at
FMR and by the supranational referral laboratory for H
and R. Sensitivity and specificity for the four individual
drugs ranged from 80– 100%, and 87–94% respectively.
As reported elsewhere [24], there was greater discordance
for observations relating to E between the two centers as
expressed by the kappa values and the sensitivity estimate.
Internal comparison also indicated a high degree of repro-
ducibility for DST (Table 2).
Discussion
The problem of MDRTB in Mumbai has been previously
highlighted [25]. A high prevalence of MDRTB strains
(11–68%) was reported in hospital based studies by 2 lab-
oratories between 1991 and 2006 [12,26] and the threats
of its transmission, stressed [27]. Unfortunately as stated
previously such data continues to be overlooked. This
study, with its emphasis on screening of RNTCP outpa-
tients from defined communities, careful selection criteria
for previously untreated and treated patients and corrob-
oration via external quality assurance was designed to pro-
vide a view of drug resistant TB in programmatically
vulnerable areas of this urban metropolis.
Inherent in the study design are three points at which bias
could have been introduced thereby leading to potential
under- or over-estimate of the prevalence of MDRTB in
previously untreated cases. Firstly, only 52% of the cases
registered with the RNTCP were screened due to reasons
mentioned in the results. Of the 48% who did not enter
the study, it is likely that a proportion would have been
excluded on the evidence of previous treatment. However
it is equally possible that the enlarged number may have
resulted in a lower rate of MDRTB than that reported here.
Thus the possibility of bias generated towards MDR by the
reduced intake prior to screening remains open. Secondly,
despite our efforts at excluding previously treated patients
during screening, it is possible that those included for DST
may not have admitted to taking prior treatment. This is a
likely cause for an overestimation of MDRTB in new cases.
Thirdly, of the 1,136 screened patients registered as new
Table 1: Drug susceptibility profiles in TB patient groups
GROUP SENSITIVE RESISTANT
MONO a) HR b) HR + E/Z/EZ MDR (a+b) POLY
First time treatment-failures
(n = 231)
39 (17) 38 (16) 13 (6) 82 (35) 95 (41) 59 (26)
Newly diagnosed (previously untreated)
(n = 493)
175 (35) 103 (21) 19 (4) 98 (20) 117 (24) 98 (20)
(Key: H: Isoniazid, R: Rifampicin, Z: Pyrazinamide, E: Ethambutol,
Figures in parentheses are %,
Polyresistance: Resistance to ≥ 2 drugs exclusive of the HR combination)Page 5 of 9
(page number not for citation purposes)
BMC Public Health 2009, 9:211 http://www.biomedcentral.com/1471-2458/9/211cases, 24% had to be excluded because they had some sort
of history of TB treatment. An additional 41% were
excluded since they had consumed more than 5 doses of
anti tubercular therapy prior to sampling (Figure 1), to
reduce bias towards MDRTB. Whilst this could tend
towards an underestimate in the total MDRTB prevalence
in the area, there could have been other selection pres-
sures that we were unable to capture in the exclusion algo-
rithm. An important example would be a history of
contact with a patient at increased risk of MDRTB (e.g. a
treatment-failure case). We did attempt in the screening to
establish connections of new cases to TB patients espe-
cially since new patients and treatment-failures accessing
a health post are drawn from the same defined geograph-
ical area which it is supposed to serve. However patients
would be unlikely to be able to articulate regarding
MDRTB in their family or vicinity.
Acknowledging the bias generated in the incorporation of
such vulnerable wards, the emphasis in patient selection
was a concerted attempt to estimate the MDRTB levels in
previously untreated cases. This was expected to offset the
drug resistance in previously treated cases that often
present to the health system as new cases. Despite this,
this study has documented high levels of multiple drug
resistance (both MDR and polyresistance) amongst previ-
ously untreated cases in the urban wards. Rifampicin
resistance has been reported to be a sentinel marker for
MDR [28]. Moreover 96% of the mutations associated
with rifampicin resistance lie within the rpoβ region [29].
Hence over and above the confidence given by external
quality assurance, genotypic corroboration of R resistance
in a subset of previously untreated and first line treat-
ment-failure cases was also obtained by the InnoLiPA line
probe assay which screens for mutations in the rpoβ gene
[29] (88% agreement, k = 0.74, data not shown).
Our initial MDRTB figures differ greatly from those
reported by the RNTCP and Indian national figures in
WHO global surveys [4-8,30,31]. The level of MDRTB in
first episode treatment failures in our study whilst less
than that reported by Rodrigues et al, 2006 (41% vs.
68%), is higher than the 17% documented by Santha et al,
2005 and Chauhan, 2008. This comparison is made diffi-
cult since definitions of treatment-failures in these publi-
cations are not precise. Nevertheless our figures remain a
cause for concern for several reasons which have been
reported earlier [32] and are outlined below.
In view of the high levels of MDRTB amongst previously
untreated patients, it is possible that a proportion of first
line treatment-failures may have had initial drug resist-
ance, which was undetected due to lack of DST facilities.
Observations in a subgroup of patients whose MDRTB sta-
tus at diagnosis and post treatment was tested in our lab-
oratory and whose treatment outcomes were recorded,
revealed that 13% (21/162) of the failures were MDR at
onset (data not shown). Alternatively, detection of MDR
at the fifth month could be due to acquisition of resist-
ance by an initially sensitive strain or a further exogenous
drug resistant strain contracted during the treatment
period [33,34].
Whilst this study was not primarily intended to determine
the prevalence of MDRTB, the linking of MDR in the treat-
ment-failures to population-based treatment outcome
rates is difficult to establish in this situation. Observations
from treatment registers for the same cohort revealed a
Cumulative proportionate increase in drug resistance in new casesFigure 2
Cumulative proportionate increase in drug resist-
ance in new cases.
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Table 2: External and Internal validity of drug susceptibility testing for individual first line drugs
EXTERNALa (n = 45) INTERNALb (n = 70)
Drugs Concordance
(%)
Kappa Values Sensitivity
(%)
Specificity
(%)
Concordance
(%)
Kappa Values
H 91 0.773 86 94 95 0.893
R 93 0.762 100 93 97 0.919
Z 87 0.557 100 87 91 0.819
E 89 0.487 80 91 90 0.759
(Key – a: Performed at Swedish Institute for Infectious Disease Control, Stockholm,
b: Repeated at FMR,
H: Isoniazid, R: Rifampicin, Z: Pyrazinamide, E: Ethambutol)Page 6 of 9
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who had defaulted during the course of their first line
treatment (data not shown). Such patients are in all like-
lihood omitted from the denominator when cure rates are
computed. This may be further compounded by the lack
of external quality assurance in sputum-smear micros-
copy. Moreover there have not been any formal external
evaluations of the validity of reported cure rates in the
national programme [35].
Whilst our observations may not be generalizable to the
entire country or even well performing wards of Mumbai,
observations from poor programme performance areas
may serve to highlight factors implicated in the develop-
ment of drug resistance [36]. These include the continued
use of intermittent therapy (discontinued by WHO since
2004), suboptimal levels of drugs in patients due to erro-
neous pattern of drug intake or drug side effects such as
vomiting and above all, the unavailability of DST facilities
among treatment-failures after first line and retreatment
regimens. Such patients will continue to transmit MDRTB
even after being readmitted to the RNTCP where Category
2 treatment {3(SHERZ)3 + 5(HRE)3} (with the addition
of only a single drug streptomycin) maybe suboptimal
[37] and where provision of diagnosis and treatment of
drug resistant TB is currently unavailable or unaffordable.
Whilst many patients from our study wards are likely to
access the RNTCP for TB treatment, the seeking of care
from private practitioners by many others and the con-
stant shopping for treatment between the public and pri-
vate sectors cannot be ignored. The contribution to
MDRTB levels from aberrant treatment practices in the
unregulated private sector has been suspected for long
and makes it likely that the levels of MDRTB revealed by
this study are an underestimate [38].
A major concern and one of great biological interest, is the
high level of resistance to 3 or even 4 first line drug com-
binations in comparison to HR alone (Table 1). Addition-
ally, the proportion of previously untreated cases resistant
to more than 3 drugs inclusive of HR was higher than that
resistant to HR alone throughout the study period (Figure
2). This scenario of amplified drug resistance suggests the
presence in this setting of a protracted, well entrenched,
evolving MDR scenario [1]. Preliminary evidence from 14
MDRTB isolates from our cohort does not reveal the pres-
ence of extensively drug resistant strains (XDR defined as
MDR strains additionally resistant to an injectable
aminoglycoside and any of the fluoroquinolones) (data
not shown). However the potential threat of XDRTB
strains in the light of several systemic and infrastructure
limitations [36,38] should not be underestimated since
their emergence within Mumbai city and elsewhere in the
country has already been documented [14,39].
Unlike the scenario in South Africa [40] and Russia [41],
the high proportion of MDRTB in Mumbai does not
appear to be greatly influenced by HIV infection, as the
seropositivity amongst our MDRTB cases (range 3–5%)
was not overtly different from the national prevalence
rates of 5% [42].
Preliminary fingerprinting studies using spoligotyping on
the same cohort of patients reveals a striking amount of
hetereogeneity in strains and overall lack of an association
between large clusters and MDRTB. The proportion of Bei-
jing, a strain known to be globally associated with MDRTB
epidemics is only 4% in the overall cohort in Mumbai and
virtually absent in the rural areas in proximity to the
metropolis. (Chatterjee et al, submitted for publication).
Cumulatively, this argues against the occurrence of a sin-
gle drug resistant strain epidemic in Mumbai.
A gradual realization of the significant presence of
MDRTB within the country is apparent from the introduc-
tion of DST for first line and retreatment failures, and pro-
vision for DOTS Plus in the RNTCP since 2007 in certain
selected areas in India. However, despite the selectivity in
study design, if initial MDRTB is high as suggested by this
and other studies [12,26], then a window for transmission
of MDRTB would remain open for 5–6 months in case of
new (first line treatment) and 8 months for retreated (Cat-
egory 2) patients.
Conclusion
Our findings strongly suggest that national estimates have
been unable to capture locale-specific variations in
MDRTB in the country largely because they originate from
sentinel sites where programme operational factors are
likely to be optimal. The data highlights systemic and
environmental factors that have been implicated in the
development of drug resistance in operationally weak
areas (such as the selected wards) and the need for drug
resistant TB surveillance to be incrementally achieved,
through regular systematic studies that randomly sample
TB patients [43] and supplement sputum microscopy
with ranked risk evaluations and/or DST (Atre et al, sub-
mitted for publication). This would entail i) the establish-
ment of quality laboratory infrastructure capable of
undertaking reliable DST in a wider set of surveillance
sites that can reflect a more balanced view of the ground
realities in vulnerable locations, ii) choice for appropriate
technology for DST and iii) judicious introduction of
DOTS Plus combined with measures of care for patients
with drug resistant TB.
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